Most-Favored-Nation pricing meets Joint Clinical Assessment: early evidence of compounding pressure on European drug launches [0.03%]
最惠国定价遇上联合临床评估：欧洲药品上市面临的证据及压力初探
Sreeram V Ramagopalan,Michael L Ryan
Sreeram V Ramagopalan
Access in all areas? A round-up of developments in market access and health technology assessment: first Joint Clinical Assessment report released [0.03%]
多领域全面市场准入吗？回顾市场准入和卫生技术评估的发展：第一次联合临床评估报告发布
Sreeram V Ramagopalan,Annie Jullien Pannelay
Sreeram V Ramagopalan
The first Joint Clinical Assessment (JCA) report has been completed. In this update we examine what this inaugural report reveals in practice and draw out the implications for manufacturers. ...
Association of physical activity levels and estimated glomerular filtration rate with all-cause mortality: a 10-year cohort study [0.03%]
运动水平和肾小球滤过率与全因死亡率关系的前瞻性队列研究
Hang Jin,Lan Cui,Jiali Liu et al.
Hang Jin et al.
Aim: Many studies have demonstrated that physical inactivity and reduced renal function are associated with an increased risk of all-cause mortality. However, most of this evidence is derived from non-Chinese populations. This study aimed t...
Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis [0.03%]
特拉鲁单抗作为美国健康保险计划中中度至重度特应性皮炎成人和青少年患者的节约成本治疗选择：预算影响分析
Reece Grindley,Linnea Houde,Aseel Bin Sawad et al.
Reece Grindley et al.
Background: Atopic dermatitis (AD) is a chronic and burdensome condition that causes intense itching and painful skin lesions and affects around 10% of adults and adolescents across the US. Potent systemic treatments, such as tralokinumab, ...
The value of time savings in breast cancer therapy for patients and healthcare providers: the subcutaneous injection of pertuzumab and trastuzumab fixed-dose combination at a tertiary care center in the UAE [0.03%]
在阿联酋一家三级护理中心接受帕妥珠单抗和曲妥珠单抗固定剂量联合注射的乳腺癌患者的节省时间的价值分析：护理提供者的角度
Khaled H A Al Qawasmeh
Khaled H A Al Qawasmeh
Aim: To measure time saving associated with the subcutaneous (SC) fixed-dose combination of pertuzumab and trastuzumab (PH FDC SC) compared with intravenous (IV) pertuzumab and trastuzumab in patients with HER2-positive breast cancer. Mater...
Directly comparing randomized and real-world controls in adjuvant breast cancer [0.03%]
直接比较辅助乳腺癌治疗的随机对照和真实世界对照
Brigham Walker,Marley Boyd,Michelle Silver et al.
Brigham Walker et al.
Aim: We sought to directly compare contemporaneous real-world (RW) and randomized controlled trial (RCT) control arms to assess the feasibility of utilizing RW controls in early breast cancer treatment. Materials & methods: Women with human...
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis [0.03%]
用于治疗经验丰富的HIV-1感染者的B/F/TAF与其它抗逆转录病毒药物方案的比较安全性：系统文献回顾和网络meta分析
Tristan Curteis,Lucy A Eddowes,Andrei Karlsson et al.
Tristan Curteis et al.
Aim: With modern antiretroviral therapy (ART), HIV-1 has now become a manageable chronic condition. Among treatment-experienced (TE) people with HIV-1 (PWH), ART regimens can influence metabolic and renal outcomes and adverse events such as...
Comparing characteristics and outcomes between hospitalized adults on a pea protein or dairy/soy protein formulas: initial findings [0.03%]
基于肽蛋白或奶蛋白/大豆蛋白配方的住院成人特征和结局比较：初步结果
Vanessa Millovich,Irene Olsen Shingara,Guilherme S Lopes et al.
Vanessa Millovich et al.
Enteral formulas are an essential part of nutrition support to prevent or treat malnutrition and minimize hospital length of stay (LOS). Yet not all formulas are tolerated and may leave nutritional needs unmet. Unique pea protein plant-base...
Estimating the societal impact of medical interventions: a case study in metastatic breast cancer [0.03%]
医疗干预的社会影响评估：转移性乳腺癌的案例研究
Foteini Tsotra,Kyle Dunton,Mats Rosenlund et al.
Foteini Tsotra et al.
Aim: Additional value elements like productivity are currently rarely included in economic evaluations since quantitative assessment may be complex or lack clear guidance. In this study we present a practical framework for estimating the so...
Economic evaluation of stapokibart for chronic rhinosinusitis with nasal polyps in China: a cost-effectiveness analysis [0.03%]
中国慢性鼻窦炎合并鼻息肉患者使用STAPOKIBART的经济性评价：一种成本效益分析方法
Jingran Yang,Lei Ren,Fengyuan Xie et al.
Jingran Yang et al.
Aim: To evaluate the cost-effectiveness of stapokibart compared with dupilumab in treating chronic rhinosinusitis with nasal polyps (CRSwNP) from the healthcare system perspective in China. The focus is on assessing the economic viability o...